title: Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
abstract: The most common pattern of emergent resistance in the phase III clinical trials of coformulated elvitegravir (EVG)-cobicistat (COBI)-emtricitabine (FTC)-tenofovir disoproxil fumarate (TDF) was the EVG resistance substitution E92Q in integrase (IN) with the FTC resistance substitution M184V in reverse transcriptase (RT), with or without the tenofovir (TFV) resistance substitution K65R. In this study, the effect of these IN and RT substitutions alone and in combination in the same genome on susceptibility to antiretroviral inhibitors and viral replication fitness was characterized. Single resistance substitutions (E92Q in IN [IN-E92Q], M184V in RT [RT-M184V], and K65R in RT [RT-K65R]) specifically affected susceptibility to the corresponding inhibitor classes, with no cross-class resistance observed. The IN-E92Q mutant displayed reduced susceptibility to EVG (50-fold), which was not impacted by the addition of RT-M184V or RT-K65R/M184V. Viruses containing RT-M184V had high-level resistance to FTC (>1,000-fold) that was not affected by the addition of IN-E92Q or RT-K65R. During pairwise growth competitions, each substitution contributed to decreased viral fitness, with the RT-K65R/M184V + IN-E92Q triple mutant being the least fit in the absence of drug. In the presence of drug concentrations approaching physiologic levels, however, drug resistance offset the replication defects, resulting in single mutants outcompeting the wild type with one drug present, and double and triple mutants outcompeting single mutants with two drugs present. Taken together, these results suggest that the reduced replication fitness and phenotypic resistance associated with RT and IN resistance substitutions are independent and additive. In the presence of multiple drugs, viral growth is favored for viruses with multiple substitutions, despite the presence of fitness defects.
authors.affiliation: Gilead Sciences, Inc., Foster City, California, USA kristen.andreatta@gilead.com.
authors.forename: Kristen N
authors.initials: KN
authors.lastname: Andreatta
authors.affiliation: Gilead Sciences, Inc., Foster City, California, USA.
authors.forename: Derrick D
authors.initials: DD
authors.lastname: Goodman
authors.affiliation: Gilead Sciences, Inc., Foster City, California, USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Miller
authors.affiliation: Gilead Sciences, Inc., Foster City, California, USA.
authors.forename: Kirsten L
authors.initials: KL
authors.lastname: White
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D002460:Cell Line; D024882:Drug Resistance, Viral / Q000235:genetics; D019427:HIV Integrase / Q000235:genetics / Q000378:metabolism*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology*; D006801:Humans; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D000068698:Tenofovir / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D019427:HIV Integrase; D054303:HIV Reverse Transcriptase
references.citation: J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85
references.pmid: 23412015
references.citation: HIV Clin Trials. 2012 Jul-Aug;13(4):228-32
references.pmid: 22849964
references.citation: PLoS One. 2013;8(6):e65631
references.pmid: 23776513
references.citation: J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e118-20
references.pmid: 24256630
references.citation: J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e121-4
references.pmid: 24346640
references.citation: Viruses. 2014 Jul;6(7):2858-79
references.pmid: 25054884
references.citation: J Virol. 2014 Aug;88(16):9268-76
references.pmid: 24899199
references.citation: Antimicrob Agents Chemother. 2014 Oct;58(10):6145-50
references.pmid: 25092710
references.citation: HIV Clin Trials. 2014 Sep-Oct;15(5):218-30
references.pmid: 25350960
references.citation: J Acquir Immune Defic Syndr. 2010 Nov;55(3):323-9
references.pmid: 20683270
references.citation: Antivir Ther. 2015;20(3):317-27
references.pmid: 25321623
references.citation: J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54
references.pmid: 21997204
references.citation: Antiviral Res. 2012 Feb;93(2):288-96
references.pmid: 22197635
references.citation: J Acquir Immune Defic Syndr. 2010 Oct;55(2):148-55
references.pmid: 20634701
references.citation: Antivir Ther. 1999;4(2):87-94
references.pmid: 10682153
references.citation: J HIV Ther. 2002 Nov;7(4):87-91
references.pmid: 12733606
references.citation: J Virol. 2004 May;78(10):5056-67
references.pmid: 15113887
references.citation: Antimicrob Agents Chemother. 1997 Dec;41(12):2781-5
references.pmid: 9420060
references.citation: J Virol. 1999 Mar;73(3):2126-35
references.pmid: 9971795
references.citation: J Virol. 2006 Mar;80(5):2380-9
references.pmid: 16474144
references.citation: J Clin Microbiol. 2006 Nov;44(11):4237-41
references.pmid: 17005757
references.citation: J Virol. 2007 Sep;81(18):10037-46
references.pmid: 17626089
references.citation: J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36
references.pmid: 18614922
references.citation: Antiviral Res. 2009 Feb;81(2):141-6
references.pmid: 19027039
references.citation: AIDS. 2010 Jan 2;24(1):17-25
references.pmid: 19770695
references.citation: JAMA. 2012 Jul 25;308(4):387-402
references.pmid: 22820792
references.citation: Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63
references.pmid: 23529738